10 research outputs found
Compliance with hand hygiene and glove use in a university-affiliated hospital
OBJECTIVE: The hands of healthcare workers often transmit pathogens causing nosocomial infections. This study examined compliance with handwashing and glove use. SETTING: A university-affiliated hospital. DESIGN: Compliance was observed covertly. Healthcare workers' demographics, hand hygiene facilities, indications for hand hygiene, compliance with handwashing and glove use in each procedure, and duration of handwashing were recorded. RESULTS: Nine nurses and 33 assistant physicians were monitored during the study. One researcher recorded 1,400 potential opportunities for handwashing during 15-minute observation periods. The mean duration of handwashing was 10 ± 2 seconds. Most healthcare workers (99.3%) used liquid soap during handwashing, but 79.8% did not dry their hands. For all indications, compliance with handwashing was 31.9% and compliance with glove use was 58.8%. Compliance with handwashing varied inversely with both the number of indications for hand hygiene and the number of patient beds in the hospital room. Compliance with handwashing was better in dirty high-risk situations. CONCLUSION: Compliance with handwashing was low, suggesting the need for new motivational strategies such as supplying feedback regarding compliance rates
Increased costs due to inappropriate surgical antibiotic prophylaxis in a university hospital [3]
Nosocomial infections in intensive care unit in a Turkish university hospital: A 2-year survey
Objective: To determine epidemiology and risk factors for nosocomial infections in intensive care unit (ICU). Design: Prospective incidence survey. Setting: An adult general ICU in a university hospital in western Turkey. Patients: All patients who stayed more than 48 h in ICU during a 2-year period (2000-2001). Measurements and results: The study included 434 patients (7394 patient-days). A total of 225 infections were identified in 113 patients (26%). The incidence and infection rates were 56.8 in 1000-patient days and 51.8%, respectively. The infections were pneumonia (40.9%), bloodstream (30.2%), urinary tract (23.6%) and surgical site infections (5.3%). Pseudomonas aeruginosa (22.6%), methicillin-resistant Staphylococcus aureus (22.2%) and Acinetobacter spp. (11.9%) were frequently isolated micro-organisms. Median length of stay with nosocomial infection and without were 13 days (Interquartile range, IQR, 20) and 2 days (IQR, 2), respectively (P<0.0001). In logistic regression analysis, mechanical ventilation [odds ratio (OR): 16. 35; 95% confidence interval (CI): 8.26-32.34; P<0.0001), coma (OR: 15.04; 95% CI: 3.41-66.33; P=0.0003), trauma (OR: 10.27; 95% CI: 2.34-45.01; P=0.002), nasogastric tube (OR: 2.94; 95% CI: 1.47-5.90; P=0.002), tracheotomy (OR: 5.77; 95% CI: 1.10-30.20; P=0.04) and APACHE II scores 10-19 (OR: 10.80; 95% CI: 1.10-106.01; P=0.04) were found to be significant risk factors for nosocomial infection. Rate of nosocomial infection increased with the number of risk factors (P<0.0001). Mortality rates were higher in infected patients than in non-infected patients (60.9 vs 22.1%; P<0.0001 ). Conclusion: These data suggest that, in addition to underlying clinical conditions, some invasive procedures can be independent risk factors for nosocomial infection in ICU
Karbapenemlerin gram-negatif patojenlere karşı in vitro aktivitelerinin karşılaştırmalı değerlendirmesi: COMPACT çalışması Türkiye verisi
The aim of this study was to determine the in vitro activities of doripenem, imipenem, and meropenem against clinical gram-negative isolates. A total of 596 clinical isolates were obtained from intensive care unit (ICU) and non-ICU patients in 10 centers over Turkey between September-December 2008. The origin of the isolates was patients with nosocomial pneumonia (42.4%), bloodstream infections (%40.4), and complicated intraabdominal infections (17.1%). Of the isolates, 51.8% were obtained from ICU patients. The study isolates consisted of Pseudomonas spp. in 49.8%, Enterobacteriaceae in 40.3%, and other gram-negative agents in 9.9%. The minimum inhibitory concentrations (MIC) for doripenem, imipenem and meropenem were determined for all isolates in each center using Etest;reg; strips (AB Biodisk, Solna, Sweden). Of the isolates, 188 (31.5%) were resistant to at least one of the carbapenems. MIC50 of doripenem against Pseudomonas spp. was 1 mg/L which was similar to that of meropenem and two-fold lower than imipenem. Susceptibility to carbapenems in P.aeruginosa was 64% for doripenem at an MIC level of 2 mg/L, 53.9% and 63% for imipenem and meropenem at an MIC level of 4 mg/L, respectively. Doripenem and meropenem showed similar activity with the MIC90 of 0.12 mg/L whereas imipenem was four-fold less active at 0.5 mg/L. Against other gramnegative pathogens, mostly Acinetobacter spp., MIC50 was 8 mg/L for doripenem and 32 mg/L for other two carbapenems. P.aeruginosa isolates were inhibited 84.2% with doripenem and 72.1% with meropenem at the MIC level of 8 mg/L. Doripenem generally showed similar or slightly better activity than meropenem and better activity than imipenem against pathogens collected in this study. Against Pseudomonas spp., doripenem was the most active of the three carbapenems. Doripenem and meropenem were equally active against Enterobacteriaceae and at least four-fold more active than imipenem. It was concluded that doripenem seemed to be a promising agent in the treatment of nosocomial pneumonia, blood stream infections and intraabdominal infections particularly in patients who were under risk of developing antimicrobial resistance.Bu çalışmada, doripenem, imipenem ve meropenemin gram-negatif klinik izolatlara karşı in vitro aktivitesinin değerlendirilmesi amaçlanmıştır. Türkiye genelinde toplam 10 merkezden Eylül-Aralık 2008 tarihleri arasında, yoğun bakım ünitesi (YBÜ) ve YBÜ dışı hastalardan, toplam 596 adet klinik izolat toplanmıştır. Bunlardan %42.4’ü nozokomiyal pnömoni, %40.4’ü kan dolaşımı enfeksiyonu ve %17.1’i komplike intraabdominal enfeksiyon kaynaklı olup; %51.8’i YBÜ hastalarından alınmıştır. İzolatların %49.8’i Pseudomonas spp., %40.3’ü Enterobacteriaceae ve %9.9’u diğer gram-negatif etkenlerden oluşmaktadır. Her merkezde Etest® (AB Biodisk, Solna, İsveç) kullanılarak tüm izolatlar için doripenem, imipenem ve meropenemin minimum inhibitör konsantrasyonu (MİK) belirlenmiştir. İzolatlardan 188 (%31.5)’i en az bir karbapeneme dirençli bulunmuştur. Pseudomonas türlerine karşı doripenem için MİK50 değerleri meropeneme benzer olarak 1 mg/L bulunurken, imipenemden iki kat daha düşük olduğu izlenmiştir. Pseudomonas aeruginosa izolatlarının duyarlılıkları, doripenem için MİK 2 mg/L düzeyinde %64, imipenem ve meropenem için MİK 4 mg/L düzeyinde sırasıyla %53.9 ve %63 olarak tespit edilmiştir. Doripenem ve meropenem, Enterobacteriaceae türlerine karşı benzer aktivite gösterirken (MİK90 0.12 mg/L), imipenem dört kat daha az aktif (0.5 mg/L) bulunmuştur. Büyük çoğunluğunu Acinetobacter türlerinin oluşturduğu diğer gram-negatif basiller için doripenem MİK50 değeri 8 mg/L, diğer iki ilaç için ise 32 mg/L’dir. P.aeruginosa izolatları 8 mg/L MİK düzeyinde doripenem ile %84.2, meropenem ile %72.1 oranında inhibe olmuştur. Sonuç olarak doripenem, bu çalışmada toplanan patojenlere karşı genel olarak meropenem ile benzer ya da daha iyi; imipenemden ise belirgin olarak daha iyi in vitro aktiviteye sahiptir. Üç karbapenem arasında Pseudomonas türlerine karşı en aktif olan ilacın doripenem olduğu görülmüştür. Doripenem ve meropenem Enterobacteriaceae türlerine karşı benzer aktiviteye sahip olup, imipenemden en az dört kat daha aktiftir. Bu bulgular ışığında, hastanede YBÜ’de ya da YBÜ dışında tedavi gören nozokomiyal pnömoni, kan dolaşımı enfeksiyonu ve intraabdominal enfeksiyonu olan hastalar ile antibiyotik direnci gelişim riski olan hastaların antimikrobiyal tedavisinde doripenemin öne çıkan yeni bir antibiyotik olduğu kanısına varılmıştır
Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in 11 adult intensive care units from 10 cities of Turkey: findings of the International Nosocomial Infection Control Consortium (INICC)
Yalcin, Ata Nevzat/0000-0002-7243-7354; Dursun, Oguz/0000-0001-5482-3780; Leblebicioglu, Hakan/0000-0002-6033-8543; dursun, oguz/0000-0001-5482-3780; UNAL, SERHAT/0000-0003-1184-4711; Geyik, Mehmet Faruk/0000-0002-0906-0902; Topeli, Arzu/0000-0002-5874-9087WOS: 000316641000020PubMed: 23355330Purpose To evaluate the impact of the International Nosocomial Infection Control Consortium (INICC) multidimensional approach on the reduction of ventilator-associated pneumonia (VAP) in adult patients hospitalized in 11 intensive care units (ICUs), from 10 hospitals, members of the INICC, in 10 cities of Turkey. Methods A prospective active before-after surveillance study was conducted to determine the effect of the INICC multidimensional approach in the VAP rate. The study was divided into two phases. In phase 1, active prospective surveillance of VAP was conducted using the definitions of the Centers for Disease Control and Prevention National Health Safety Network, and the INICC methods. In phase 2, we implemented the multidimensional approach for VAP. The INICC multidimensional approach included the following measures: (1) bundle of infection control interventions, (2) education, (3) outcome surveillance, (4) process surveillance, (5) feedback of VAP rates, and (6) performance feedback of infection control practices. We compared the rates of VAP obtained in each phase. A time series analysis was performed to assess the impact of our approach. Results In phase 1, we recorded 2,376 mechanical ventilator (MV)-days, and in phase 2, after implementing the multidimensional approach, we recorded 28,181 MV-days. The rate of VAP was 31.14 per 1,000 MV-days during phase 1, and 16.82 per 1,000 MV-days during phase 2, amounting to a 46 % VAP rate reduction (RR, 0.54; 95 % CI, 0.42-0.7; P value, 0.0001.) Conclusions The INICC multidimensional approach was associated with a significant reduction in the VAP rate in these adult ICUs of Turkey.Foundation to Fight against Nosocomial InfectionsThe authors thank the many health care professionals at each member hospital who assisted with the conduct of surveillance in their hospital, including the surveillance nurses, clinical microbiology laboratory personnel, and the physicians and nurses providing care for the patients during the study; without their cooperation and generous assistance this INICC would not be possible; Mariano Vilar, Debora Lopez Burgardt, Santiago Suarez, Cecilia Cappelini, Denise Brito, Eugenia Manfredi, Luciana Soken, Dario Pizzuto, Yuan Ding, Katie Saunders, and Isaac Kelmeszes who work at INICC headquarters in Buenos Aires, for their hard work and commitment to achieve INICC goals; the INICC country coordinators (Altaf Ahmed, Carlos A. Alvarez Moreno, Anucha Apisarnthanarak, Luis E. Cuellar, Bijie Hu, Hakan Leblebicioglu, Eduardo A. Medeiros, Yatin Mehta, Lul Raka, Namita Jaggi, and Toshihiro Mitsuda); the INICC Advisory Board (Carla J. Alvarado, Gary L. French, Nicholas Graves, William R. Jarvis, Patricia Lynch, Dennis Maki, Russell N. Olmsted, Didier Pittet, Wing Hong Seto, Syed Sattar, and William Rutala), who have so generously supported this unique international infection control network; and specially to Patricia Lynch, who inspired and supported us to follow our dreams despite obstacles. The funding for the activities carried out at INICC head quarters were provided by the corresponding author, Victor D. Rosenthal, and Foundation to Fight against Nosocomial Infections
Impact of a multidimensional infection control approach on catheter-associated urinary tract infection rates in adult intensive care units in 10 cities of Turkey: International Nosocomial Infection Control Consortium findings (INICC)
Yalcin, Ata Nevzat/0000-0002-7243-7354; dursun, oguz/0000-0001-5482-3780; Geyik, Mehmet Faruk/0000-0002-0906-0902; Dursun, Oguz/0000-0001-5482-3780; Leblebicioglu, Hakan/0000-0002-6033-8543; Unal, Necmettin/0000-0002-9440-7893WOS: 000325254600011PubMed: 23623158Background: We evaluate the effectiveness of a multidimensional infection control approach for the reduction of catheter-associated urinary tract infections (CAUTIs) in 13 intensive care units (ICUs) in 10 hospital members of the International Nosocomial Infection Control Consortium (INICC) from 10 cities of Turkey. Methods: A before-after prospective active surveillance study was used to determine rates of CAUTI. The study was divided into baseline (phase 1) and intervention (phase 2). In phase 1, surveillance was performed applying the definitions of the Centers for Disease Control and Prevention/National Healthcare Safety Network. In phase 2, we implemented a multidimensional approach that included bundle of infection control interventions, education, surveillance and feedback on CAUTI rates, process surveillance, and performance feedback. We used random effects Poisson regression to account for clustering of CAUTI rates across time periods. Results: The study included 4,231 patients, hospitalized in 13 ICUs, in 10 hospitals, in 10 cities, during 49,644 patient-days. We recorded a total of 41,871 urinary catheter (UC)-days: 5,080 in phase 1 and 36,791 in phase 2. During phase 1, the rate of CAUTI was 10.63 per 1,000 UC-days and was significantly decreased by 47% in phase 2 to 5.65 per 1,000 UC-days (relative risk, 0.53; 95% confidence interval: 0.4-0.7; P value = .0001). Conclusion: Our multidimensional approach was associated with a significant reduction in the rates of CAUTI in Turkey. Copyright (C) 2013 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.Foundation to Fight against Nosocomial InfectionsFunding for the activities carried out at INICC headquarters were provided by the corresponding author, Victor D. Rosenthal, and the Foundation to Fight against Nosocomial Infections
Safety Evaluation and Tolerability Overview of Favipiravir in the Management of COVID-19: A Real-Life Experience from Turkey
Introduction: Coronavirus diseases-2019 (COVID-19) have been ongoing for more than two years. Despite the scientific researchconducted in this process, there is still no widely accepted definitive treatment for the disease. For treating COVID-19, using antiviralagents previously used for the treatment of other RNA-virus infections has been seen as a fast way to a solution, and favipiravir is oneof the leading agents. This prospective, multicenter, observational study was designed to investigate the safety of favipiravir in 500patients treated with favipravir for favipravir.Methods: This study was conducted as a multicenter prospective study. Eight different sites from four cities participated, and 500patients were included in the study. Follow-up of laboratory parameters, adverse events (AEs), and amelioration of fever, dyspnea,and cough symptoms of the patients was recorded in a case report form.Results: A total of 475 patients from eight centers completed the study. A total of 401 AEs were reported in 206 (51.4%) patients, whichwere mild-to-moderate in the majority of cases. Serious AEs occurred in 5 patients and death occurred in 4 patients. From the first tothe last measurement, serum alanine aminotransferase levels (31.9±27.7 vs. 47.2±49.7 U/L, p<0.001) increased, whereas C-reactiveprotein (39.9±66.4 vs. 15.2±30.5 mg/L, p<0.001) and creatine kinase (101.7±187.7 vs. 71.9±43.5 U/L, p=0.018) levels decreased. Infollow-up parameters, oxygen saturation (SpO2; 96.2±2.7 vs. 97.5±2.1%, p<0.001) and amelioration of fever (>37.8 for 6.6% on day 3,3.2% on day 5, and 0.6% on day 10), dyspnea (for 56.4% on day 5, 62.4% on day 7, and 81.2% on day 10), and cough (46.0% on day 5,73.0% on day 7, and 87.3% on day 10) were noted in an increasingly higher percentage of patients with continued therapy.Conclusion: The current study provides real-life data of favipiravir, which is a unique option in Turkey for treating COVID-19 patients.The results revealed that favipiravir is a well-tolerated agent with a low side-effect profile. However, it needs to be evaluated withwell-designed, dose-compared, randomized controlled studies for the evaluation of efficacy</p
A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004–2005
Recommended from our members
International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2013-2018, Adult and Pediatric Units, Device-associated Module
•Data from 428,847 patients, 2,815,402 bed-days.•We collected 1,468,216 line days, 1,053,330 ventilator days, 1,740,776 urinary catheter days.•We found 7,785 CLAB, 12,085 VAE, and 5,509 CAUTI.•HAI rates were 5.91% and 9.01 HAIs/1,000 bed-days.•CLAB rate was 5.3/1000 CL-days; VAE rate was 11.4/1000 MV-days, CAUTI rate was 3.1/1000 UC-days.
We report the results of INICC surveillance study from 2013 to 2018, in 664 intensive care units (ICUs) in 133 cities, of 45 countries, from Latin-America, Europe, Africa, Eastern-Mediterranean, Southeast-Asia, and Western-Pacific.
Prospective data from patients hospitalized in ICUs were collected through INICC Surveillance Online System. CDC-NHSN definitions for device-associated healthcare-associated infection (DA-HAI) were applied.
We collected data from 428,847 patients, for an aggregate of 2,815,402 bed-days, 1,468,216 central line (CL)-days, 1,053,330 mechanical ventilator (MV)-days, 1,740,776 urinary catheter (UC)-days. We found 7,785 CL-associated bloodstream infections (CLAB), 12,085 ventilator-associated events (VAE), and 5,509 UC-associated urinary tract infections (CAUTI). Pooled DA-HAI rates were 5.91% and 9.01 DA-HAIs/1,000 bed-days. Pooled CLAB rate was 5.30/1,000 CL-days; VAE rate was 11.47/1,000 MV-days, and CAUTI rate was 3.16/1,000 UC-days. P aeruginosa was non-susceptible (NS) to imipenem in 52.72% of cases; to colistin in 10.38%; to ceftazidime in 50%; to ciprofloxacin in 40.28%; and to amikacin in 34.05%. Klebsiella spp was NS to imipenem in 49.16%; to ceftazidime in 78.01%; to ciprofloxacin in 66.26%; and to amikacin in 42.45%. coagulase-negative Staphylococci and S aureus were NS to oxacillin in 91.44% and 56.03%, respectively. Enterococcus spp was NS to vancomycin in 42.31% of the cases.
DA-HAI rates and bacterial resistance are high and continuous efforts are needed to reduce them